RFA-DA-24-034: Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 23, 2025.
From the official notice on Grants.gov, last changed May 15, 2025. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-24-034 in the NIH Guide.
Key dates
| Posted | September 29, 2023 |
|---|---|
| Deadline | May 23, 2025 |
| Archived by Grants.gov | June 22, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Past Diabetes, Digestive, and Kidney Diseases Extramural Research awards averaged $1.2 million; this notice allows up to $500,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage clinical research that will identify and validate novel targets for non-invasive brain stimulation (NIBS) and SUD-relevant neurobiological, cognitive, and behavioral responses to NIBS that precede clinical outcomes like reduced craving or drug use. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS.This NOFO uses a R61/R33 Phased Innovation award activity code to support applications that propose mechanistic studies designed to understand a behavior or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention. In addition, applications must meet the NIH definition of a clinical trial. NIH defines a clinical trial as A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. (NOT-OD-15-015)
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-24-034 still open?
No. It closed on May 23, 2025.
Who can apply for Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)?
Closed May 23, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)